No Phase 3 clinical trials have been completed
It is not for human consumption, veterinary, medical, or cosmetic use, and no directions for use are given
Similarly, for Ipamorelin, pharmacokinetic/pharmacodynamic modelling underscores inter-individual variability, so clinician oversight for dose, frequency, and lab monitoring is needed
At therapeutic IV doses (often 2550 g in oncology and critical-care research), studies report improvements in inflammation markers, oxidative stress, and quality of life in advanced cancer and sepsis, although evidence is strongest for adjunctive rather than standalone use
That means that you may be able to use it later in the day without risking a restless night